Alfuzosin for the management of benign prostate hyperplasia

Bibliography

• BERRY SJ, COFFEY DS, WALSH PC, EWING LL: The development of human benign prostatic hyperplasia with age. Ural (1984) 132:474–479.
   PubMed Web of Science ®Google Scholar
• BUZELIN JM, ROTH S, GEFFRIAUD-RICOUARD C, DELAUCHE-CAVALLIER MC: Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. ALEGBI Study Group. Eur: Ural. (1997b) 31:190–198.
   Google Scholar
• JARDIN A, BENSADOWN H, DELAUCHE-CAVALLIER MC, ATTALLI P: Alfuzosin for the treatment of benign prostatic hyperplasia. The BPH-ALF Group. Lancet (1991) 337:1457–1460.
   PubMed Web of Science ®Google Scholar
• TEILLAC P, DELAUCHE-CAVALLIER MC, ATTALI P: Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. The DUALF Group.Br.Uml. (1992) 70:58–64.
   PubMedGoogle Scholar
• LUKAS B, BLONDIN P, MCCARTHY C, DUBOYS B, GRIPPON P, LASSALE C: Safety profile of 3-month therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur. Ural (1996) 29:29–35.
   PubMedGoogle Scholar
• AHTOY P, CHRETIEN P, DUPAIN T, RAUCH C, ROUCHOUSE A, DELFOLIE A: Alfuzosin, an alpha-1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthysubjects. Int. J. Clin. Pharm. Ther. (2002) 40(7):289–294.
   PubMedGoogle Scholar
• RAUCH-DESANTI C, FRAISSE J, DUBRUC C, MAHRAOUI L, THENOT JP: Pharmacokinetics and metabolic profiles of alfuzosin. In: Benign prostatic hyperplasia - the place of alfuzosin. Debruyne FMJ, Jardin A, Roehrborn CJ, Langer SZ (Eds), Adis International. (1998):63–73.
   Google Scholar
• CAINE M, PAZ S, ZIEGLER M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br. J. Urol. (1975) 27:193–202.
   Google Scholar
• DJAVAN B, MARBERGER M: A meta-analysis of the efficacy and tolerability of alpha-1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur. Urol. (1999) 36:1–13.
   PubMed Web of Science ®Google Scholar
• BASAR MM, ATAN A, OZERGIN 0, YILDIZ M: The efficacy of alfuzosin treatment in patients with prostatism. Urol. Nephrol. (2001) 33:493–497.
   Google Scholar
• LEFEVRE-BORG F, LECHAIRE J, O'CONNOR S: In vivo uroselectivity of alfuzosin compared to prazosin and terazosin. Br: J. Pharmacol. (1992) 106: 84.
   Web of Science ®Google Scholar
• ROUQUIER Y, CLAUSTRE Y, BENAVIDES J: Alpha-1 -adrenoceptor antagonists differentially control serotonin release in the hippocampus and striatum: a microdialysis study. Eur. Pharmacol. (1994) 261:59–64.
   PubMed Web of Science ®Google Scholar
• BUZELIN JM,DELAUCHE-CAVALLIER MC, ROTH S, GEFFRAIUD-RICOUARD C, SANTONI JP: Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br. J. Urol. (1997) 79:898–906.
   PubMedGoogle Scholar
• LUKACS B, MCCARTHY C,GRANGE JC: Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with alpha-1 adrenergic blocker alfuzosin. The QOL BPH Study Group In General Practice. Eur. Urol. (1993) 24\(Suppl. 1):34–47.
   Google Scholar
• PERRIGOT M,DELAUCHE-CAVALLIER MC, AMARENCO G, GEFFRIAUD C, STALLA-BOURDILLON A, COSTA P: Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladderdisease. The Dorali Study Group. Neurourol. Urodynam. (1996) 15:119–131.
   PubMed Web of Science ®Google Scholar
• LEPOR H: Non operative management ofbenign prostatic hypertrophy. Urol. (1989) 141:1283–1289.
   Google Scholar
• BUZELIN JM, HERBERT M, BLONDIN P: Alpha blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The Prazalf Group. Br. J. Urol. (1993) 72:922–927.
   PubMedGoogle Scholar
• STEPHENSON TP, JENSEN RD AND THE PRANALF GROUP: A placebo-controlled study of the efficacy and tolerability of alfuzosin and prazosin for the treatment of benign prostatic hypertrophy (BPH). Proceedings XP Congress of the European Association of Urology Berlin Germany. (1994) 25(Abstract 48).
   Google Scholar
• LOWE FC: Safety assessment of terazosinin the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology (1994) 44:46–51.
   PubMed Web of Science ®Google Scholar
• JANKNEGT RA, CHAPPLE CR: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. The Doxazosin Study Groups. Eur. Urol. (1993) 24:319–326.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, SCHULMAN CC, VAAGE S: Tamsulosin. A selective alpha- lc adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Br J. Urol. (1995) 76:325–336.
   Google Scholar
• CAVALLINI G: Alpha-1 blockade pharmacotherapy in primative psychogenic premature ejaculation resistant to psychotherapy. Ear: Urol. (1995) 28:126–130.
   PubMed Web of Science ®Google Scholar
• DEBRUYNE FMJ, VAN DER POEL HG: Clinical experience in europe with uroselective alpha-1-antagonists. Ear: Urol. (1999) 36\(Suppl. 1):54–58.
   Google Scholar
• LUCAS B, GRANGE JC, MCCARTHY C, COMET D: Clinical uroselectivity: a 3 year follow up in general practice. BPH _ _roup In General Practice. Eur. Urol. (1998) 33\(Suppl. 2):28–33.
   Google Scholar
• BUZELIN JM,DELAUCHE-CAVALLIER MC, ROTH S, GEFFRIAUD-RICOUARD C, SANTONI JP: Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomaticbenign prostatic obstruction. Br. J. Urol. (1997) 79:898–906.
   PubMedGoogle Scholar
• DEBRUYNE FMJ, JARDIN A, COLLOI D et al: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. The European Alfin Study Group. Eur. Urol. (1998) 34:169–175.
   PubMedGoogle Scholar
• HOFNER K, JONAS U: Alfuzosin: a clinically uroselective alpha-1-blocker. World J. Urol. (2002) 19:405–412.
   PubMed Web of Science ®Google Scholar
• DE LA ROSETTE J, KORTMANN B, ROSSI C, SONKE G, FLORATOS D, KIEMENEY L: Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.Urol. (2002) 167:1734–1739.
   Google Scholar
• FORRAY C, NOBLE SA: Subtype selectivealpha-1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opin. Investig. Drugs (1999) 8(12):2073–2094.
   PubMedGoogle Scholar
• MARTIN DJ, ANGEL I, ARBILLA S: Functional uroselectivity. Eur. Urol. (1998) 33\(Suppl. 2):12–18.
   Google Scholar
• ECKERT RE, SCHREIER U,ALLOUSSI S et al: Zellulare Grundlage der dynamischen, infravesikalen Obstruktion im Rahmen der benignen Prostatahyperplasie: Rolle von Alpharezeptorenblockern und zyklischen Nukleotiden. Akt Ural. (1998) 29:252–260.
   Google Scholar
• LOWE FC, DJAVAN R: Prospective randomized trial to evaluate the side effect profile of tamsulosin versus terazosin in 1983 men with benign prostatic hyperplasia. Urol. 167(4):267 (Abstract 1032).
   Google Scholar
• ROEHRBORN CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology (2001) 58(6A):55–64.
   Google Scholar
• MCKEAGE K, PLOSKER GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs (2000) 62(4):633–653.
   Google Scholar
• WILDE MI, FITTON A, MCTAVISH D: Alfuzosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs (1993) 45(3):410–429.
   PubMed Web of Science ®Google Scholar
• VAN KERREBROECK EV: The efficacy and safety of a new once-a-day formulation of an alpha-blocker. Eur. Urol. (2001) 39\(Suppl. 6):19–26.
   Google Scholar
• ALLHAT COLLABORATIVE RESEARCH GROUP: Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2000) 283:1967–1975.
   PubMed Web of Science ®Google Scholar